SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-24-017817
Filing Date
2024-01-29
Accepted
2024-01-29 13:14:26
Documents
9

Document Format Files

Seq Description Document Type Size
1 DEFM14A d35957ddefm14a.htm DEFM14A 1371837
2 GRAPHIC g35957dsp001.jpg GRAPHIC 1101
3 GRAPHIC g35957dsp1a.jpg GRAPHIC 1522
4 GRAPHIC g35957dsp1b.jpg GRAPHIC 1224
5 GRAPHIC g35957dsp1d.jpg GRAPHIC 1883
6 GRAPHIC g35957dsp2.jpg GRAPHIC 1898
7 GRAPHIC g35957g17g68.jpg GRAPHIC 51076
8 GRAPHIC g35957snap1.jpg GRAPHIC 2013
9 GRAPHIC g35957snap2.jpg GRAPHIC 1054
  Complete submission text file 0001193125-24-017817.txt   1459164
Mailing Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037
Business Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037 (858) 875-2400
Ambrx Biopharma, Inc. (Filer) CIK: 0001990550 (see all company filings)

IRS No.: 932892120 | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 000-56600 | Film No.: 24572409
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)